U.S. Machinery Stock News

NYSE:DV
NYSE:DVMedia

A Look At DoubleVerify Holdings (DV) Valuation As AI Disruption Fears Pressure Enterprise Software Stocks

DoubleVerify Holdings (DV) came under pressure after new generative AI models from Anthropic and OpenAI showed they can automate complex software auditing and code management, prompting investors to reassess potential long term demand for some enterprise software offerings. See our latest analysis for DoubleVerify Holdings. Beyond the latest AI concerns, DoubleVerify’s share price has been weak for some time, with a 7 day share price return of 13.68% and a 1 year total shareholder return...
NYSE:AM
NYSE:AMOil and Gas

Is Antero Midstream (AM) Pricing Reflect Its Strong Multi‑Year Share Price Performance

Wondering if Antero Midstream at around US$19.18 is offering fair value or if the market is missing something? This article walks through the key signals that matter for you. The stock has recent returns of 1.9% over 7 days, 10.8% over 30 days, 6.9% year to date, 25.4% over 1 year, 116.4% over 3 years and 205.3% over 5 years, which gives useful context before you weigh up what you are paying today. Recent attention on Antero Midstream has focused on its role as an energy infrastructure...
NasdaqGS:JAZZ
NasdaqGS:JAZZPharmaceuticals

Jazz Pharmaceuticals (JAZZ) Valuation After HERIZON GEA Trial Upside And Planned 2026 sBLA Filing

Jazz Pharmaceuticals (NasdaqGS:JAZZ) is back in focus after practice changing HERIZON GEA trial results and plans to file a supplemental Biologics License Application in 2026 for first line gastroesophageal adenocarcinoma therapies. See our latest analysis for Jazz Pharmaceuticals. Investors have responded positively to the HERIZON GEA update, with a 24.26% 90 day share price return from Jazz Pharmaceuticals and a 37.58% 1 year total shareholder return, suggesting momentum has picked up...
NasdaqGM:RLAY
NasdaqGM:RLAYBiotechs

Assessing Relay Therapeutics (RLAY) Valuation After Recent Share Price Momentum And Price To Book Discount

Why Relay Therapeutics (RLAY) is on investors’ radar Relay Therapeutics (RLAY) has drawn attention after a strong stretch of share price performance, including a positive move over the past month and an even stronger gain in the past 3 months. See our latest analysis for Relay Therapeutics. At a latest share price of $8.92, Relay Therapeutics has seen momentum build, with a 1 day share price return of 9.45% and a 90 day share price return of 44.57%, while the 1 year total shareholder return...
NYSE:ZGN
NYSE:ZGNLuxury

Assessing Ermenegildo Zegna (ZGN) Valuation After Q4 Growth Acceleration And UBS Upgrade

Ermenegildo Zegna (ZGN) is back in focus after reporting unaudited fourth quarter and full year 2025 revenues and receiving an upgrade from UBS, which has drawn fresh attention to the company’s recent operating trends. See our latest analysis for Ermenegildo Zegna. The latest unaudited revenue update and the UBS upgrade have come alongside a sharp rebound in sentiment, with a 7 day share price return of 19.56% and a 1 year total shareholder return of 20.47%. This suggests momentum has...
NasdaqGS:BPOP
NasdaqGS:BPOPBanks

Why Popular (BPOP) Is Up 9.3% After Strong 2025 Earnings And Share Buybacks

Popular, Inc. recently reported full-year 2025 results showing higher net interest income of US$2,541.2 million and net income of US$833.16 million, and it also disclosed lower quarterly net charge-offs alongside ongoing preferred and trust preferred dividend payments. The company further reinforced shareholder returns by completing a share repurchase of 1,847,274 shares for US$218.83 million while continuing regular income distributions on its hybrid securities. With earnings strength and...
NasdaqCM:ISPR
NasdaqCM:ISPRTobacco

Ispire Technology (ISPR) Loss Of US$6.6m In Q2 2026 Reinforces Bearish Narratives

Ispire Technology (NasdaqCM:ISPR) opened Q2 2026 with total revenue of about US$20.3 million and a basic EPS loss of US$0.12, alongside a net income loss of roughly US$6.6 million. This frames a clear focus on how efficiently that revenue is translating into earnings. The company has reported quarterly revenue between about US$20.1 million and US$41.8 million over the past six reported periods, while basic EPS has ranged from a loss of US$0.06 to a loss of US$0.26, giving investors a concrete...
NasdaqGS:RBBN
NasdaqGS:RBBNCommunications

Ribbon Communications (RBBN) Is Down 25.2% After Swinging To 2025 Profit And Cutting 2026 Outlook – Has The Bull Case Changed?

Ribbon Communications Inc. recently reported its Q4 and full-year 2025 results, with Q4 revenue of US$227.32 million and net income of US$89.07 million, alongside issuing 2026 revenue guidance of US$160 million to US$170 million for Q1 and US$840 million to US$875 million for the full year. An interesting shift in 2025 was the move from a full-year net loss of US$54.24 million to net income of US$39.64 million, highlighting a materially improved bottom line despite relatively stable annual...